Introduction {#S1}
============

Rett syndrome (RTT) is a pervasive disorder of neuronal plasticity, characterized by an apparent normal early development, followed by a stagnation and regression of development, leading to loss of purposeful hand movements, reduced brain and head growth, physical disabilities, language and learning deficits, seizures, and intellectual disability (Rett, [@B43]; Hagberg et al., [@B24]). Most patients first exhibit symptoms between 6 and 18 months of age and display the hallmark clinical course of progressive loss of cognitive function and fine and gross motor skills, and abnormal social-cognitive development (Williamson and Christodoulou, [@B52]).

In most cases, RTT is caused by *de novo* mutations in the X-linked methyl-CpG-binding (*MECP2*) gene (Christodoulou and Weaving, [@B13]), resulting in the disruption of the molecular functions of MeCP2. MeCP2 is predominantly expressed in the brain and particularly in post-mitotic neurons, where its level of expression correlates with the maturation of the central nervous system (Pelka et al., [@B37]). The distinct neurological phenotype of RTT patients demonstrates that MeCP2 regulation is essential for normal neuronal and brain development and function (Swanberg et al., [@B50]). The broad clinical phenotype of RTT may make clinical diagnosis a challenge, particularly in mutation-negative patients where a definitive genetic result cannot be used. However, consensus criteria have been established that distinguish RTT patients into the individual classifications of "classic" or "typical" RTT and the "atypical" or "variant" forms of RTT (Neul et al., [@B34]).

Despite severe neurological and associated behavioral abnormalities observed in RTT, there are no overt differences in the gross structure of the brains in RTT patients (Chahrour and Zoghbi, [@B11]). However, the number of studies showing structural and morphological synaptic defects (Armstrong et al., [@B3], [@B4]; Bauman et al., [@B8]; Kishi and Macklis, [@B27]; Belichenko et al., [@B9]), reduced synapse number (Belichenko et al., [@B9]), and synaptic and circuitry deficits (Fukuda et al., [@B19]; Asaka et al., [@B5]; Moretti et al., [@B32]; Guy et al., [@B23]; Zhang et al., [@B54]; Lonetti et al., [@B30]) highlights the synaptic dysfunction associated with RTT.

To date, over 800 pathogenic mutations have been detected within the *MECP2* gene (RettBASE; Christodoulou et al., [@B12])[^1^](#fn1){ref-type="fn"}. These mutations include a range of missense, nonsense, frameshift, and in-frame insertions or deletions, as well as large deletions spanning whole exons or even the entire gene. Approximately 80--85% of the known MECP2 mutations are localized within the methyl-binding domain (MBD), transcription repression domain (TRD), and C-terminal domain, creating "hot-spot" areas of mutations (Figure [1](#F1){ref-type="fig"}).

![**Distribution of known mutations along the *MECP2* gene**. The red lines indicate the frequency of the mutations. The numbers 1--487 refer to the amino acids along the MeCP2 polypeptide. MDB, methyl-binding domain; TRD, transcription repression domain (RettBASE: <http://mecp2.chw.edu.au>) (Williamson and Christodoulou, [@B52]).](fncel-09-00266-g001){#F1}

The *MECP2* gene is alternatively spliced, generating two isoforms *MECP2E1* (previously referred to as *MECP2B* or *MECP2*α) and *MECP2E2* (previously referred to as *MeCP2A* or *MECP2*β) (Kriaucionis and Bird, [@B29]; Mnatzakanian et al., [@B31]). The *MeCP2E1* isoform uses the translation start site (ATG) in exon 1 and comprises exons 1, 3, and 4, and is the predominant isoform in the central nervous system, whereas the *MeCP2E2* isoform uses a translation start site in exon 2 and comprises exons 2, 3, and 4. Both isoforms share MBD, TRD, and C-terminal domains, characteristic of *MECP2*.

Although the majority of RTT patients have mutations in the *MECP2* gene (Neul et al., [@B33]), approximately 8% of classical RTT and 42% of variant RTT patients are *MECP2* mutation negative (Percy, [@B38]). Of this latter group of individuals, some have mutations in other genes, such as cyclin-dependent kinase-like 5 (*CDKL5)*, Forkhead box protein G1 (*FOXG1)*, myocyte-specific enhancer factor 2C (*MEF2C*), and transcription factor 4 (*TF4*) (Evans et al., [@B16]; Philippe et al., [@B40]; Armani et al., [@B2]). Interestingly, known RTT-causing *MECP2* mutations are found in patients who do not show classical RTT phenotypes (Suter et al., [@B49]), as well as in patients with PPM-X syndrome (Klauck et al., [@B28]), and an "Angelman-like syndrome" clinical picture (Watson et al., [@B51]). Of note, there still remain a subset of patients with a clinical diagnosis of RTT that are mutation negative.

Implications in Screening RTT Patients for *MECP2* Mutations {#S2}
============================================================

Historically, exon 1 of the *MECP2E1* isoform was excluded from sequencing and mutation analysis in RTT patients as it was thought to be a non-coding exon. However, since the discovery of the *MECP2E1* isoform, mutation analysis of exon 1 has been included and to date, a number of mutations involving exon 1 have been reported in RTT patients (Ravn et al., [@B42]; Bartholdi et al., [@B7]; Chunshu et al., [@B14]; Quenard et al., [@B41]; Saxena et al., [@B48]; Saunders et al., [@B47]; Gianakopoulos et al., [@B20]). Initially, mutations in exon 1 were suggested to be rare in RTT patients as detection rates were found to be between 0.03 and 1% of tested RTT patients (Amir et al., [@B1]; Evans et al., [@B17]; Quenard et al., [@B41]). It has also been suggested that RTT patients with mutations in exon 1 have a more severe phenotype than patients without exon 1 mutations (Bartholdi et al., [@B7]).

To date, no mutations have been reported in exon 2 encoding for the *MeCP2E2* isoform. Mouse studies showing the maternally transferred *Mecp2e2* null allele resulted in reduced embryonic viability, suggesting a likely explanation for the absence of exon 2-specific mutations in RTT patients. Interestingly, some patients with atypical RTT phenotypes, who are *MECP2* mutation negative, show abnormal expression of both *MECP2* isoforms (Petel-Galil et al., [@B39]), suggesting that other genes may regulate *MECP2* expression.

Recent developments in massively parallel DNA sequencing (also known as next-generation sequencing; NGS) now allow for cost-efficient sequencing of entire exomes (whole-exome sequence; WES) or even the complete genome (whole-genome sequencing; WGS), enabling the efficient identification of novel variants in known disease genes, as well as facilitating the discovery of novel disease genes. NGS is emerging as a new tool for the identification of novel genes in complex genetic disorders, such as RTT. To date, a small number of studies have emerged identifying new disease genes associated with RTT. These studies are discussed below and highlight the utility of NGS in identifying new disease genes in RTT patients.

Recent Studies Using NGS in "RTT" Patients {#S3}
==========================================

In 2014, WES unveiled a variation in the gamma-aminobutyric acid receptor delta gene (*GABRD*) in a 12-year-old female patient diagnosed with an RTT-like clinical picture (Okamoto et al., [@B36]). The patient had severe intellectual disability, hypotonia, and a stereotypic behavior, "hand gripping," described as being typical of RTT, bruxism, and exhibited no purposeful hand skills, was unable to walk independently, and could not articulate any meaningful words. She also had short stature, was underweight, and had microcephaly. Her EEG showed bilateral occipital dominant high-voltage slow spike and wave complexes. Her brain CT and MRI were normal. To determine the underlying genetic cause in this patient, WES was performed, which revealed two *de novo* missense variations in adjacent amino acids in the *GABRD* gene (c.498G \> A: p.Met166Ile and c.499G \> A: p.Asp167Asn) (Okamoto et al., [@B36]), making this the first report of a mutation in the *GABRD* gene in a patient with an RTT-like disorder. *GABRD* is located on chromosome 1p36, encodes a subunit of the ligand-gated chloride channel for the major inhibitory neurotransmitter gamma-aminobutyric acid (GABA) (Windpassinger et al., [@B53]), and is highly expressed in the brain. Based on the knowledge that mutations in GABA~A~ receptor subunit genes and in *GABRD* are associated with genetic epilepsy syndromes (Emberger et al., [@B15]), and the observation that patients with 1p36 deletion syndrome often have seizures (Rosenfeld et al., [@B45]), this suggests that the variation observed in the *GABRD* gene is likely to cause increased neuronal excitability. However, these authors did not provide any *in silico* evidence to support pathogenicity of these variations. From our *in silico* predictions, MutationTaster[^2^](#fn2){ref-type="fn"} predicts these mutations to be "disease causing" with a probability of 0.9999 due to amino acid sequence changes in a highly conserved region, which is predicted to affect splicing. In addition, Polyphen[^3^](#fn3){ref-type="fn"} predicts both of them to be "probably damaging" with a score of 0.969 and PROVEAN[^4^](#fn4){ref-type="fn"} predicts them to be "deleterious" with scores of −3.670 and −4.576, respectively (where the cut-off score is −2.5). Regardless of these predictions, it was not determined whether these two variations were in *cis* or *trans* and no functional studies to support the pathogenicity of RTT were reported. Moreover, our interrogation of the literature failed to identify other *GABRD* mutation-positive cases exhibiting phenotypic overlap with RTT. Accordingly for now, the contention of these authors that mutations in *GABRD* could cause RTT must be cast in doubt.

In another recent case report of a 6-year-old Japanese girl initially reported to have an RTT-like phenotype, WES identified a variation in the WD repeat domain 45 (*WDR45*) gene (Okamoto et al., [@B35]). The patient's development was reported to be normal for the first 10 months, after which she developed stereotypic hand-wringing and finger-sucking behavior typical of RTT, and poor eye contact (which is not typical of *MECP2* mutation-positive "classic" RTT patients). She subsequently developed seizures and her EEG showed diffuse spike-wave and polyspike-wave bursts. Her MRI showed delayed myelination and enlarged lateral ventricles. At 5 years of age, she was noted to be dysmorphic (including hypertelorism, epicanthal folds, flat nasal bridge, bilateral low-set ears, downslanting palpebral fissures, short philtrum, high palate, downturned mouth, and micrognathia), had spasticity of lower limbs and bruxism, was unable to walk independently, had intellectual disability, and had no meaningful speech. Array CGH was normal as was molecular testing for RTT, although it was not stipulated which genes were screened or how. WES revealed a heterozygous *de novo* nonsense mutation causing an early termination in the X-linked WD repeat domain 45 (*WDR45*) gene (c.868C \> T: p.Gln290\*). Mutations of *WDR45* have been reported to cause β-propeller protein-associated neurodegeneration (BPAN), characterized by early intellectual disability, followed by progressive motor and cognitive deterioration with onset in the second to third decade. This particular variation has not been previously reported in the *WDR45* gene and our *in silico* analysis reveals it to be "disease causing" with a high probability of 1, according to MutationTaster and even "deleterious" according to PROVEAN with a score of −5.656, highlighting the severity of this variation and its impact on pathogenicity. Patients with BPAN show a typical picture of brain iron accumulation on MRI, and indeed a subsequent MRI in this patient showed such abnormalities. Stereotypic hand movements, including hand wringing and flapping, have been reported in patients with BPAN (Saitsu et al., [@B46]) and in fact in another study, 23 BPAN patients were suspected to have atypical RTT (Hayflick et al., [@B25]), suggesting an overlap in symptoms between these disorders. Again, the authors did not show any functional data to confirm the pathogenicity of this variation and it could be speculated that this variation may not necessarily be contributing to the RTT phenotype of the patient. The careful evaluation of all available clinical and laboratory data in *MECP2* mutation-negative patients with RTT-like symptoms in interpreting genomic sequencing data is essential. In both these cases, a definitive classification of RTT was not noted. Neither girl was reported to demonstrate a period of developmental regression, and thus we can conclude that they did not have the classical form of RTT, but rather an RTT-like phenotype overlapping with BPAN. It can only be assumed that the dysmorphic features are a consequence of the primary genetic disorder, as facial dysmorphism is not a feature of RTT.

Whole-exome sequence has also been used to recently identify a variation in the *CDKL5* gene in a 5-year-old Japanese boy with intractable epilepsy, severe developmental delay, and RTT-like features (Kato et al., [@B26]). Variations in *CDKL*5 are associated with epileptic encephalopathy (Bahi-Buisson et al., [@B6]). At the age of 2 months, he contracted a respiratory-syncytial virus and developed non-febrile cluster clonic convulsions. Computed tomography and MRI of the brain and EEG were all normal at that time. He continued to have tonic seizures several times a day and EEG showed sporadic single polyspikes and diffuse irregular polyspikes. At 17 months, motor and developmental delay was evident: he could sit unaided but could not crawl, could not follow with his eyes, speak any meaningful words, or stand unaided. He continued to have intractable seizures and an abnormal EEG. WES revealed variations in the two genes, *CDKL5* and *KCNQ2*. The variation in *CDKL5* was a *de novo* hemizygous mutation in (c.119C \> T, p.Ala40Val), which has been previously reported to be responsible for early infantile epileptic encephalopathy (Rosas-Vargas et al., [@B44]). He was also heterozygous for a paternally inherited previously reported variation in the potassium voltage-gated channel, KQT-like subfamily, member 2 gene (*KCNQ2*) (c.1545G \> C, p.Glu515Asp). Mutations in this gene cause benign familial neonatal seizures, and so it seems unlikely that this variation has contributed to this child's epileptic encephalopathy, but this is not easily testable. CDKL5-related encephalopathy is an X-linked dominant disorder that is characterized by early infantile epileptic encephalopathy that is clinically distinct from RTT (Fehr et al., [@B18]). These findings highlight the utility of WES in identifying the etiology of the complex infantile seizure disorder in this patient.

Another study, by Grillo and colleagues, explored the prospect of RTT being a complex genetic disorder using WES. They studied two pairs of sisters with pathogenic *MECP2* mutations (the c.1157del32 mutation inherited from their mother in one pair of sisters, and an apparently *de novo MECP2* deletion including exon 3 and part of exon 4, respectively, in the other pair of sisters) (Grillo et al., [@B22]). Although the sisters shared the same *MECP2* mutation, they were discordant in their clinical severity, which could be explained by differences in skewing of X-chromosome inactivation. Whole-exome sequencing revealed variations in a number of genes involved in oxidative stress, muscle impairment, and intellectual disability and/or autism in the more severely affected individuals, whereas their sisters with a milder RTT phenotype had variations in genes related to the regulation of the immune system. Whether these variants were of functional relevance in these sisters remains an open question, but this study raises the interesting prospect that NGS strategies could potentially unmask genetic modifiers of phenotypic severity in *MECP2* mutation-positive RTT patients, which could in turn point to potential novel therapeutic targets.

Gilissen and colleagues used WGS to identify large deletions in patients with RTT (Gilissen et al., [@B21]). In one girl with a clinical diagnosis of RTT, an intra-exonic deletion within exon 4 of the *MECP2* gene was identified, which for technical reasons had been missed by Sanger sequencing and MLPA analysis performed in a diagnostic laboratory. In the same study, another patient with RTT-like symptoms was identified to have a single exon deletion in the structural maintenance of chromosomes 1A (*SMC1A*) gene. This patient had some features seen in RTT (severe intellectual disability, microcephaly, stereotypic movements, short stature, and scoliosis), but also had features not at all typical of RTT (facial dysmorphism, cleft palate, cataracts, tapered fingers, and brain MRI abnormalities). Mutations in *SMC1A* cause Cornelia de Lange syndrome, and in retrospect this child's clinical picture was a good fit for this disorder. These cases highlight the power of WGS to identify sub-exonic deletions in patients with RTT or disorders that may share some features with RTT, and emphasize the potential utility of NGS, in particular WGS, to efficiently identify existing disease genes in patients with complex phenotypes.

Challenges of NGS and Moving Beyond the Exome {#S4}
=============================================

Whole-exome sequence is emerging as an effective approach to identify known and even novel causative genes in patients with RTT or RTT-like phenotypes, offering comprehensive coverage of the majority of the coding regions of the genome. However, there are some limitations in the technology. These include potentially poor coverage of GC rich or repetitive regions, the fact that the target enrichment strategies do not include non-coding regions, such as introns, 3′-UTR and 5′-UTR regions, and the inability to easily detect structural variations, such as inversions, copy number variations, and translocations, although bioinformatics resources are improving the capacity to identify such structural variations (Bellos and Coin, [@B10]). As WGS costs fall and the analysis of massive genomic sequencing data files improve with time, WGS may prove to be a more efficient and cost-effective option to screen for variations in RTT patients.

This report highlights the emerging utility of NGS for the identification of known and novel genes in patients with RTT and overlapping clinical phenotypes. The real utility in NGS lies particularly in the differential genetic diagnosis for the variant forms of the disorder and the discovery of potential genetic modifiers of phenotypic severity. The utilization of this technology will allow for the definitive diagnosis of RTT patients who are mutation negative and will reveal avenues for future translational research targeting new disease genes. WES may open doors for the discovery of new disease genes in RTT and related phenotypes. However, caution must be exercised to ensure that a clinical diagnosis of classical or variant RTT is robust, and care must be taken to prevent overinterpretation of genomic sequencing data. Before such discoveries could be considered to be genuinely pathogenic in RTT patients robust bioinformatic analyses must be performed, supported by clear *in vitro* and/or *in vivo* evidence of functional perturbation.
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